Skip to main content

Ethics and Sustanibility in Pharmacy

Climate change and the biodiversity crisis pose major ethical challenges for healthcare systems. This is particularly relevant because healthcare itself is a significant driver of climate change and environmental pollution, accounting for around 5% of global CO₂ emissions. This research area addresses the normative and ethical challenges associated with the green transformation of healthcare, with a particular focus on pharmaceuticals.

What this is about

Pharmaceuticals are an essential part of healthcare – modern medical treatment is hardly conceivable without them. However, they also account for a substantial share of healthcare’s environmental and climate impact. Moreover, affluent countries in particular face considerable overuse of pharmaceuticals and other medical products and services.

How can this overuse be reduced without denying individuals their human right to high-quality and comprehensive healthcare? What changes are needed at the meso and macro levels, and how should they be assessed from a social ethics perspective?

These questions are addressed within the research area “Ethics & Sustainability in Pharmacy.” Current research focuses particularly on the normative-ethical and functional aspects of sustainable market access.

What we research

Green & Sustainable Market Access

Market-access management involves negotiating pharmaceutical prices that balance the interests of stakeholders and reflect the actual “value” of a product. If sustainability constitutes a value dimension of pharmaceuticals, the question arises as to how this dimension can be integrated into existing market-access mechanisms.

Governance and Regulation

Market-access mechanisms are currently shaped primarily at the European and national levels. So far, sustainability considerations have played only a minor role. This is critically examined from a social ethics perspective, as sustainable market-access mechanisms could integrate economic incentives for greater sustainability into existing regulatory frameworks.

Pharmaceutical Supply Chains

Pharmaceutical supply chains can involve thousands of stakeholders across the globe. Environmental impacts therefore do not arise only where pharmaceuticals are purchased and consumed. Particularly severe environmental and social impacts often occur in poorer regions of the Global South. This raises global ethical challenges that extend beyond German or European regulatory frameworks.

Socio-Ethical Conceptualization

Sustainability in healthcare can conflict with considerations of justice – for example, ensuring broad and comprehensive access to medicines for all. To address this tension, the research develops reform proposals based on the common good and subsidiarity, seeking to balance different interests without restricting patients’ individual rights to treatment and healthcare.

Project team

Publications

Publications

Nguyen, B. (2026): Late-Stage Benefit Assessment as an Environmental Impact Assessment. A Policy Proposal for the OneHealth Debate in the German Healthcare System (Die späte Nutzenbewertung als Umweltfolgenabschätzung. Ein Policy-Vorschlag zur OneHealth-Debatte im deutschen Gesundheitswesen), in: Gesundheits- und Sozialpolitik, 1/2026. P. 48-54. DOI: 10.5771/1611-5821-2026-1-48

Nguyen, B. (2026):
 Planetary Health Technology Assessment: Designing a Late-Stage Benefit Assessment as an Environmental Impact Assessment for New Drugs (Planetary Health Technology Assessment: Konzeption einer späten Nutzenbewertung als Umweltfolgenabschätzung für neue Arzneimittel), in: RPG (23/3) 2026, P. 65-71.  

Nguyen, B. / DGIV (2025):
Position Paper by the Sustainability Working Group of the “German Society for Integrated Care” (DGIV): Using Public Bidding to Achieve Greater Environmental Sustainability in the Healthcare System (Positionspapier der AG Nachhaltigkeit der„Deutschen Gesellschaft für Integrierte Versorgung“ (DGIV): Mit Ausschreibungen zu mehr ökologischer Nachhaltigkeit im Gesundheitswesen), available at: https://dgiv.org/wp-content/uploads/2025/07/AG-Nachhaltigkeit_Positionspapier_Ausschreibungen.pdf 

Roth, B.
(2023): Green Choice Tariffs. A Policy Proposal for the OneHealth Debate in the German Healthcare System (Grüne Wahltarife. Ein policy-Vorschlag zur OneHealth-Debatte im deutschen Gesundheitswesen), in: Gesundheits- und Sozialpolitik, 4-5/2023. P. 71-79. DOI: 10.5771/1611-5821-2023-4-5-71

Roth, B. Hollis, A, Kistler, S., Matthey, M.,  Ngcobo, Z. (2023): The Green Impact Fund for Technology: An Application of Homann’s Ethics of Order? (Der Green Impact Fund for Technology: Ein Anwendungsbeispiel für die Homann`sche Ordnungsethik?), in: Zeitschrift für Wirtschafts- und Unternehmensethik (zfwu) 24 (2). P. 164-183.DOI: https://doi.org/https://doi.org/10.5771/1439-880X2023-2-164 

Ethics and Sustainability in Pharmacy